DiaSorin (OTCMKTS:DSRLF) Downgraded to “Strong Sell” Rating by Zacks Research

DiaSorin (OTCMKTS:DSRLF) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other analysts have also issued reports on the stock. UBS Group lowered shares of DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. BNP Paribas Exane cut shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 7th. Piper Sandler started coverage on shares of DiaSorin in a research note on Thursday, June 11th. They set a “neutral” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of DiaSorin in a research report on Tuesday. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

DiaSorin Trading Up 5.6%

Shares of OTCMKTS:DSRLF opened at $85.56 on Thursday. The firm’s 50 day moving average price is $79.59 and its 200-day moving average price is $76.58. DiaSorin has a twelve month low of $66.50 and a twelve month high of $100.00.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.